Genmab | GEN - Ativo Circulante





Ativo Circulante Alterar Data
Agios Pharmaceuticals USD 752.1M 34.43M 2026-09
Almirall EUR 747.1M 33.12M 2026-06
Amarin USD 612.88M 10.12M 2026-09
Amgen USD 34.36B 598M 2026-09
argenx SE USD 8.07B 1.17B 2026-06
AstraZeneca USD 31.45B 3.48B 2026-09
Bayer EUR 39.6B 5.96B 2026-09
BioMarin Pharmaceutical USD 3.92B 50.99M 2026-09
Demant DKK 10.2B 130M 2026-06
Exelixis USD 1.32B 70.8M 2026-09
Fresenius Medical Care EUR 7.84B 150.6M 2026-09
Genmab DKK 2.8B 228M 2026-06
GlaxoSmithKline GBP 17.9B 336M 2026-09
GN Store Nord DKK 20.15B 14.52B 2026-09
GRIFOLS EUR 5.35B 40M 2026-09
Hikma Pharmaceutical USD 2.64B 86M 2025-12
Insmed USD 1.71B 72.59M 2026-09
Lakefront Biotherapeutics EUR 2.31B 751.38M 2026-06
Lonza CHF 8B 3.41B 2025-12
Merck EUR 13.77B 393M 2026-06
Novartis USD 28.75B 1.4B 2026-09
Regeneron Pharmaceuticals USD 20.8B 2.35B 2026-09
Roche Holding CHF 35.44B 3.29B 2026-06
Sanofi EUR 33.21B 1.68B 2026-09
UCB EUR 6.05B 733M 2025-12